Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

Matteo Lambertini; Niels Kroman; Lieveke Ameye; Octavi Cordoba; Alvaro Pinto; Giovanni Benedetti; Maj-Britt Jensen; Shari Gelber; Maria Del Grande; Michail Ignatiadis; Evandro de Azambuja; Marianne Paesmans; Fedro A Peccatori; Hatem A Azim

doi:10.1093/jnci/djx206

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

Matteo Lambertini, Niels Kroman, Lieveke Ameye, Octavi Cordoba, Alvaro Pinto, Giovanni Benedetti, Maj-Britt Jensen, Shari Gelber, Maria Del Grande, Michail Ignatiadis, Evandro de Azambuja, Marianne Paesmans, Fedro A Peccatori, Hatem A Azim

Institut for Klinisk Medicin

64 Citationer (Scopus)

Abstract

Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

Originalsprog	Engelsk
Tidsskrift	Journal of the National Cancer Institute
Vol/bind	110
Udgave nummer	4
Sider (fra-til)	426-429
ISSN	0027-8874
DOI	https://doi.org/10.1093/jnci/djx206
Status	Udgivet - 1 apr. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1093/jnci/djx206

djx206.pdfForlagets udgivne version, 680 KB

Citationsformater

Lambertini, M., Kroman, N., Ameye, L., Cordoba, O., Pinto, A., Benedetti, G., Jensen, M-B., Gelber, S., Del Grande, M., Ignatiadis, M., de Azambuja, E., Paesmans, M., Peccatori, F. A., & Azim, H. A. (2018). Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. Journal of the National Cancer Institute, 110(4), 426-429. https://doi.org/10.1093/jnci/djx206

Lambertini, M, Kroman, N, Ameye, L, Cordoba, O, Pinto, A, Benedetti, G, Jensen, M-B, Gelber, S, Del Grande, M, Ignatiadis, M, de Azambuja, E, Paesmans, M, Peccatori, FA & Azim, HA 2018, 'Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status', Journal of the National Cancer Institute, bind 110, nr. 4, s. 426-429. https://doi.org/10.1093/jnci/djx206

@article{22842a4a8d6f4307872a2b973f355df4,

title = "Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status",

abstract = "Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.",

author = "Matteo Lambertini and Niels Kroman and Lieveke Ameye and Octavi Cordoba and Alvaro Pinto and Giovanni Benedetti and Maj-Britt Jensen and Shari Gelber and {Del Grande}, Maria and Michail Ignatiadis and {de Azambuja}, Evandro and Marianne Paesmans and Peccatori, {Fedro A} and Azim, {Hatem A}",

year = "2018",

month = apr,

day = "1",

doi = "10.1093/jnci/djx206",

language = "English",

volume = "110",

pages = "426--429",

journal = "National Cancer Institute. Journal (Print)",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

AU - Lambertini, Matteo

AU - Kroman, Niels

AU - Ameye, Lieveke

AU - Cordoba, Octavi

AU - Pinto, Alvaro

AU - Benedetti, Giovanni

AU - Jensen, Maj-Britt

AU - Gelber, Shari

AU - Del Grande, Maria

AU - Ignatiadis, Michail

AU - de Azambuja, Evandro

AU - Paesmans, Marianne

AU - Peccatori, Fedro A

AU - Azim, Hatem A

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

AB - Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

U2 - 10.1093/jnci/djx206

DO - 10.1093/jnci/djx206

M3 - Journal article

C2 - 29087485

SN - 0027-8874

VL - 110

SP - 426

EP - 429

JO - National Cancer Institute. Journal (Print)

JF - National Cancer Institute. Journal (Print)

IS - 4

ER -

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater